Is There a Link Between Clopidogrel Resistance and Common Risk Factors for Atherosclerosis in Patients with Acute Coronary Syndrome?

2017 ◽  
Vol 68 (11) ◽  
pp. 2726-2730
Author(s):  
Irina Iuliana Costache ◽  
Florin Mitu ◽  
Razan Al Namat ◽  
Iuliu Ivanov ◽  
Roxana Popescu ◽  
...  

The antiplatelet effect of clopidogrel prodrug is characterized by a wide inter-individual variability that has a significant clinical relevance. Among varios factors that are involved in the occurrence of clopidogrel resistance, the genetic polymorphisms play a key role. The aim of the present study was to investigate the impact of some risk factors for atherosclerosis on the antiplatelet effect of clopidogrel in patients with acute coronary syndrome and the possible correlation with metabolizer phenotype of patients based on CYP2C19 polymorfisms. We found a statistically significant correlation (p value [ 0.05) between smoking or dyslipidaemia and the presence of ultrarapid metabolizer phenotype for clopidogrel in our research population.

Author(s):  
Ritu Attri ◽  
Harsimran Kaur ◽  
Raminderpal Singh Sibia ◽  
Mandip Singh Bhatia

Introduction: CAD is the most common cause of mortality in India. It is a common multifarious public health crisis today and a leading cause of morbidity and mortality in both developing and developed countries. Hence, understanding the predominant risk factors among the Indian population is important. Materials and Methods: This was a hospital based age and sex matched case control study, carried out at Government Medical College and Rajindra Hospital Patiala. A total of 100 patients of Acute coronary syndrome were studied. Patients and controls were enquired about  the presence of cardiometabolic risk factors and the significance of association of these risk factors with the occurrence of Acute coronary syndrome was given by p value of  <0.05. Results: Majority of the cases were in the age group 61-70 years (32%) with male to female ratio  of 1.25:1. Significant association was found between ACS and risk factors like smoking, positive family history of IHD, hypertension, diabetes, dyslipidemia, waist hip ratio and body mass index. Overall, most common outcome of ACS in the present study was NSTEMI (45%) followed by STEMI (35%) followed by Unstable angina (20%). Conclusion: Significant association was found between smoking and occurrence of STEMI and significant association was found between Hypertension and occurrence of NSTEMI.


2019 ◽  
Vol 8 ◽  
pp. 204800401985195
Author(s):  
D Abreu ◽  
FJ Pinto ◽  
C Matias-Dias ◽  
P Sousa

Introduction Efforts were made to improve management of coronary disease as the fast-track system to the Coronary Unit. We aim to analyse case-fatality rates by acute coronary syndrome in Portugal from 2000 to 2016, mainly the impact of the fast-track system and the proportion of patients that activate the fast-track system. Methods We analysed monthly acute coronary syndrome case-fatality before and after the implementation of the fast-track system in 2007. Impact of the system was assessed through regression models for interrupted time-series. We calculated annual proportion of fast-track system admissions. Results After 2007 case-fatality by acute coronary syndrome decreased (β=−1.27, p-value < 0.01). The estimates obtained for ST Elevation Myocardial Infarction suggest a reduction of nearly 86 monthly deaths prevented after 2007. The highest percentage of patients admitted through the fast-track system was 35%. Conclusions Our results suggest fast-track system may have contributed to a decline in acute coronary syndrome case-fatality. However, more than half of patients were not admitted through the system. This should encourage health authorities to make efforts to ensure compliance.


2021 ◽  
Vol 8 (6) ◽  
pp. 835
Author(s):  
Shubhangi Verma ◽  
Omkar Kamble

Background: Acute coronary syndrome (ACS) refers to clinical symptoms pertaining to acute myocardial infarction. Bilirubin is an antioxidant that helps in removal of excessive heme. The aim of the study was to find the association of ACS and other risk factors for ACS with the total bilirubin levels in our setup.Methods: A cross sectional observational study was conducted on 100 cases attending the department of medicine in a Dr. Panjabrao Deshmukh Memorial Medical College, Amravati, Maharashtra. Patients fitting the eligibility criteria were subjected to data collection which was done using pre-designed case record form. The case record form had details of demography, detailed clinical history, physical examination and relevant investigations.Results: The mean age of the cases was 55.64±10.23 years with male preponderance. Majority of the patients presented with chest pain (83%) followed by shortness of breath (65%) and nausea/vomiting (33%). There was moderate significant correlation between total bilirubin levels and LDL levels (r=0.703; p value<0.001) and There was mild significant correlation between total bilirubin levels and TGs (r=0.403, p value<0.001) Based on the median value of 0.48 as cut off, 33% had bilirubin levels more than 0.48. Presence of diabetes and hyperlipidemias had significant association with the total bilirubin levels.Conclusions: Nearly 1/3rd of the patients in our study had high bilirubin levels. Higher bilirubin levels correlated well with presence of diabetes and presence of hyperlipidemias.  There was significant correlation between the serum LDL and TG levels with total bilirubin levels in the present study.


2016 ◽  
Vol 8 (3) ◽  
pp. 173
Author(s):  
Idar Mappangara ◽  
Ali Aspar Mappahya ◽  
Sheila Witjaksono

BACKGROUND: Identifying risk factors for acute coronary syndrome (ACS) is important for both diagnostic and prognostic purposes. Abnormal platelet parameters, mainly platelet count (PC), mean platelet volume (MPV) and platelet distribution width (PDW) are thought to be among these risk factors because platelet activation plays a pivotal role in ACS. PDW is a more specific marker of platelet activation, since it does not increase during simple platelet swelling. In this study, the comparison of risk factors along with the PDW between Non ST-Elevation ACS (NSTEACS) and ST-Elevation ACS (STEACS) were investigated.METHODS: This is a cross-sectional study, patients with ACS that admitted at dr.Wahidin Sudirohusodo General Hospital Makassar since December 2014 to March 2015 who undergo coronary angiography were enrolled. All data variables were taken according to the medical record. PDW was taken on first blood examination at hospital admission. Data was significant if p-value <0.05 and was processed with SPSS version 16.RESULTS: A total of 63 patients were enrolled. There were significantly higher PDW (p=0.047) in STEACS group (13.7±2.0 fL) than in NSTEACS group (12.6±2.3 fL). There were a significant positive correlation between PDW value and SYNTAX scores (Pearson, r=0.552, p=0.000). Cardiovascular risk factors such as history of ACS before (p=0.049 & OR=10.216) and dyslipidemia (p=0.049 & OR=3.915) along with PDW (p=0.003 & OR=1.733) were significant predictor of the incidence of multivessel disease in patient with ACS.CONCLUSION: An increased PDW may predicting more severe disease in ACS based on incidence of STEACS and multivessel disease more often and higher SYNTAX score.KEYWORDS: platelet distribution width, PDW, acute coronary syndrome, ACS, multivessel disease, SYNTAX


2019 ◽  
Vol 78 (5) ◽  
pp. 683-687 ◽  
Author(s):  
Helga Westerlind ◽  
Marie Holmqvist ◽  
Lotta Ljung ◽  
Thomas Frisell ◽  
Johan Askling

ObjectivesTo investigate a potential shared susceptibility between rheumatoid arthritis (RA) and acute coronary syndrome (ACS) by estimation of the risk of ACS among full siblings of patients with RA.MethodsBy linking nation-wide Swedish registers, we identified a cohort of patients with new-onset RA 1996–2016, age- and sex-matched (5:1) general population comparator subjects, full siblings of RA and comparator subjects, and incident ACS events through 31 December 2016. We used Cox regression to estimate the HR of ACS among patients with RA and the siblings of patients with RA versus the general population, overall and stratified by RA serostatus. We explored the impact of traditional cardiovascular (CV) risk factors on the observed associations.ResultsWe identified 8109 patients with incident RA, and 11 562 full siblings of these. Compared with the general population, the HR of ACS in RA was 1.46 (95% CI 1.28 to 1.67) and 1.22 (95% CI 1.09 to 1.38) among their siblings. The increased risks seemed confined to seropositive RA (patients: 1.52 [1.30 to 1.79], their siblings: 1.27 [1.10 to 1.46]); no significant risk increase was observed among siblings of patients with seronegative RA (HR 1.13 [95% CI 0.92 to 1.39]). Adjustment for 19 traditional CV risk factors did not appreciably alter these associations.ConclusionSiblings of patients with RA are at increased risk of ACS, suggesting shared susceptibility between RA and ACS, indicating the need and potential for additional cardio-preventive measures in RA (and their siblings).


2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 115.1-116
Author(s):  
P. Drivelegka ◽  
L. T. H. Jacobsson ◽  
U. Lindström ◽  
K. Bengtsson ◽  
M. Dehlin

Background:Gout is associated with an increased risk of cardiovascular disease (CVD), but it is not clear whether this risk is intrinsic to gout itself or to underlying comorbidities. Although the impact of gout on CVD has been studied previously, the results have been conflicting and studies from European countries are scarce.Objectives:To investigate the risk of first-time acute coronary syndrome (ACS) in patients with incident gout in western Sweden, compared to the general population.Methods:Using data from the population-based health care database VEGA, we identified all patients with incident gout diagnosis at either primary or specialized health care units in western Sweden, in the period 2007– 2017 (20,287 cases; mean age, 65.6 years; 67.4% males). Cases regarded as incident, if they did not have any recorded diagnosis of gout in the previous seven years. For each case, up to five controls matched on age, sex, and county at the date of first gout diagnosis were identified from the census register (84,240 controls). Cases and controls with prior history of ischemic heart disease were excluded. The follow-up began at the first diagnosis of gout, and ended at the earliest of an ACS event, emigration, death, or 31 December 2017. To estimate the risk of first-time ACS, we used incident rate (IR) and univariable and multivariable Cox regression analysis with adjustments for the following cardiovascular risk factors: the diagnoses of hypertension, diabetes, hyperlipidemia, obesity, renal disease, heart failure, cardiomyopathy, psoriasis, chronic obstructive pulmonary disease, alcoholism, cancer, cerebrovascular, and atherosclerotic disease, as well as for the dispensed prescriptions of statins, anticoagulants, anti-hypertensive, anti-diabetic, anti-hyperlipidemic, anti-obesity, and vasodilator drugs.Results:The IR of first-time ACS was 9.0 events per 1,000 person-years in the gout cohort, compared to 6.3 in the control cohort. The IRs were lower for women than men, both in the gout (IR, 8.2 vs 9.4) and in the control cohort (IR, 5.0 vs 7.0). Univariable analysis showed that patients with gout have a higher risk of first-time ACS, as compared to the general population (Figure 1, Table 1), but the increased risk is largely diminished after adjustments for cardiovascular risk factors (Table 1).Table 1.Risk of first-time ACS in patients with incident gout, as compared to the general population.Unadjusted HR95% CIp-valueAdjusted HR95% CIp-valueACS Overall1.431.32-1.55<.00011.151.05-1.240.0013 Men1.351.23-1.48<.00011.121.02-1.230.0230 Women1.631.41-1.89<.00011.211.03-1.410.0207Figure 1.Event-free survival curve for patients with gout and controls during the follow-up, where event is first-time acute coronary syndrome.Conclusion:Patients with incident gout have a 43% higher risk of first-time ACS, as compared to the general population. This increased risk is largely explained by the increased occurrence of comorbidities in gout, but there is still a modestly increased risk that may be due to gout related factors. Our results underline the importance of cardiovascular risk assessment and the need for appropriate management of the underlying cardiovascular risk factors in patients with gout.Disclosure of Interests:None declared


2021 ◽  
Vol 8 ◽  
Author(s):  
Grigorios Tsigkas ◽  
Eleni-Evangelia Koufou ◽  
Konstantinos Katsanos ◽  
Panagiotis Patrinos ◽  
Athanasios Moulias ◽  
...  

Aims: To evaluate the impact of lockdown during the COVID-19 pandemic on lifestyle changes of the general population, and on admissions for acute coronary syndrome (ACS).Methods and Results: All ACS admissions during the COVID-19 lockdown (10 March to 4 May, 2020), in 3 municipalities (3 spoke, and 1 hub hospital), in Southwestern Greece (411,576 inhabitants), were prospectively recorded and compared to the equivalent periods during 2018, and 2019. A telephone survey of 1014 participants was conducted to explore the lifestyle habits of citizens aged ≥35-years-old before and during lockdown. The median ACS incidence rate decreased from 19.0 cases per week in 2018 and 21.5 in 2019 down to 13.0 in 2020 (RR: 0.66 during the Covid-19 lockdown; 95%CI: 0.53–0.82; P = 0.0002). This was driven by a significant reduction of admissions for Non-ST elevation myocardial infarction (NSTEMI) (RR: 0.68; 95%CI: 0.52–0.88; P = 0.0037), mainly in patients with a lower burden of cardiovascular risk factors, as we noticed an inverse association between the reduction of the incidence of ACS during the Covid-19 lockdown period and the number of registered patient risk factors. There was no difference in the rates of STEMI and population-based all-cause mortality across the examined time periods. The telephone survey demonstrated reduction of passive smoking, working hours, alcohol, junk food and salt consumption, and an increase in sleeping hours, mainly in participants with a lower burden of cardiovascular risk factors.Conclusions: A significant decline in ACS admissions during the COVID-19 lockdown was noted, affecting mainly NSTEMI patients with a lower burden of cardiovascular risk factors. This was accompanied by significant lifestyle changes. Thus, it is tempting to speculate that to some extend the latter might be associated with the observed decline in ACS admissions.


2019 ◽  
Vol 72 (11) ◽  
Author(s):  
Yulian H. Kyyak ◽  
Olga Yu. Barnett ◽  
Marta P. Halkevych ◽  
Olha Ye. Labinska ◽  
Hryhoriy Yu. Kyyak ◽  
...  

2019 ◽  
Vol 72 (11) ◽  
Author(s):  
Yulian H. Kyyak ◽  
Olga Yu. Barnett ◽  
Marta P. Halkevych ◽  
Olha Ye. Labinska ◽  
Hryhoriy Yu. Kyyak ◽  
...  

2021 ◽  
Vol 8 (1) ◽  
pp. e000840
Author(s):  
Lianne Parkin ◽  
Sheila Williams ◽  
David Barson ◽  
Katrina Sharples ◽  
Simon Horsburgh ◽  
...  

BackgroundCardiovascular comorbidity is common among patients with chronic obstructive pulmonary disease (COPD) and there is concern that long-acting bronchodilators (long-acting muscarinic antagonists (LAMAs) and long-acting beta2 agonists (LABAs)) may further increase the risk of acute coronary events. Information about the impact of treatment intensification on acute coronary syndrome (ACS) risk in real-world settings is limited. We undertook a nationwide nested case–control study to estimate the risk of ACS in users of both a LAMA and a LABA relative to users of a LAMA.MethodsWe used routinely collected national health and pharmaceutical dispensing data to establish a cohort of patients aged >45 years who initiated long-acting bronchodilator therapy for COPD between 1 February 2006 and 30 December 2013. Fatal and non-fatal ACS events during follow-up were identified using hospital discharge and mortality records. For each case we used risk set sampling to randomly select up to 10 controls, matched by date of birth, sex, date of cohort entry (first LAMA and/or LABA dispensing), and COPD severity.ResultsFrom the cohort (n=83 417), we identified 5399 ACS cases during 281 292 person-years of follow-up. Compared with current use of LAMA therapy, current use of LAMA and LABA dual therapy was associated with a higher risk of ACS (OR 1.28 (95% CI 1.13 to 1.44)). The OR in an analysis restricted to fatal cases was 1.46 (95% CI 1.12 to 1.91).ConclusionIn real-world clinical practice, use of two versus one long-acting bronchodilator by people with COPD is associated with a higher risk of ACS.


Sign in / Sign up

Export Citation Format

Share Document